- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02733965
Impact of Clinical Pharmacy Consultations in Patients With Cancer Treated With Oral Anti-cancer Therapies on the Rate of Serious Adverse Events (PharmaOnco)
The improvement of the care pathway of oncology patients through Clinical Pharmacy activities for outpatients (such as pharmaceutical consultation) should be implemented and evaluated.
In order to improve the care pathway of patients on anticancer oral therapies, The investigators suggest in this research project to integrate into the medical care a "Clinical Pharmacy follow-up" for the patient at the hospital in the form of "pharmaceutical consultations". These pharmaceutical consultations carried out in coordination with the hospital clinical teams also aim to make the link between the hospital and community pharmacists.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The improvement of the care pathway of oncology patients through Clinical Pharmacy activities for outpatients (such as pharmaceutical consultation) should be implemented and evaluated.
In order to improve the care pathway of patients on anticancer oral therapies, the investigators suggest in this research project to integrate into the medical care a "Clinical Pharmacy follow-up" for the patient at the hospital in the form of "pharmaceutical consultations". These pharmaceutical consultations carried out in coordination with the hospital clinical teams also aim to make the link between the hospital and community pharmacists. These pharmaceutical consultations were initiated in Marseille and Grenoble University Hospitals in order to know the special needs of patients under oral chemotherapies. However, the impact of these pharmaceutical consultations in a population of patients receiving ambulatory oral therapy remains unknown and needs to be evaluated using objective criteria such as the rate of adverse events which the consequences are considerable both for the patient and the society.
These observations prompted us to establish a randomized controlled study with the objective of assessing the impact of the Clinical Pharmacy consultations in cancer patients treated with oral anti-cancer therapies on the general care management: occurrence of serious adverse events (primary outcome).
This bicenter, prospective, randomized, placebo-controlled, open-label, two-parallel group study is performed to assess the efficacy of pharmaceutical consultations in the experimental group (full clinical medication review) and pharmaceutical interviews in the control group (Patient Therapeutic Education for oral anticancer drugs only). Depending on the result of the randomization the patient will find himself in one of those 2 parallel arms:
- Control group: standard course + short pharmaceutical interviews (therapeutic education)
- Experimental group: standard course + long pharmaceutical consultations (including full clinical medication review and therapeutic education)
Control group: therapeutic education through short pharmaceutical interviews
The patients allocated in the control group will have a "classic" course of treatment. They will receive the best medical care and will be offered to participate in the therapeutic education program in place in the participating centers including:
- An educational assessment consisting on evaluating the patient's educational needs.
- Group workshops entitled "Disease and drugs", "Dietary and sports activity", "Psychology Workshop" during which the patient will be able to participate in order to get all the information he needs.
- Individual therapeutic education sessions to specifically and personally highlight certain non-pharmaceutical educational needs identified at the time of the educational assessment.
Moreover, in the control arm, a systematic "short pharmaceutical interview" with an average duration of 15 minutes will be proposed to patients at the initiation of treatment, at D15 after the prescription (considered as the date of inclusion) at M1 and then every 3 months (M3, M6, M9 and M12):
- Dosage, including the maximum dosage for modular taken drugs
- Duration of treatment
- User precautions
- The necessary information to drug use
- Any special precautions to be taken and any information relevant to the good understanding of the treatment by the patient
- Biological analyzes necessary for the initiation, monitoring, and pursuit of certain treatments
Experimental group: Clinical Pharmacy through Long Pharmaceutical Consultations In this experimental group, patients will receive the same course of treatment as the patients in the control group, including the D0 short pharmaceutical interview, with the same prerogatives of acceptance or rejection of participation in the TPE program. Short pharmaceutical interviews from D15 to M12 will be replaced by long pharmaceutical consultations of 30 to 60 minutes. The latter consisting in a full clinical medication review and incorporating the pedagogic aspects addressed in the short pharmaceutical interviews but for all therapeutic drugs taken by the patient. Additional consultations are possible on the request of the oncologist and/or patient. The consultations carried out at the request of the oncologist and/or the patient will be counted.
The first part of the pharmaceutical consultation focuses on a complete clinical medication review including:
- Establishment of the patient profile: medical history, drug allergies and intolerance, comorbidities, age, understanding capacities, organizational capacity…
- Establishment of the list of current treatments (cancer treatment, treatment of comorbidities, self-medication, other products). The effective use of drugs will be discussed with the patient.
Study of health behaviors:
- Concerning self-medication (reasons, active ingredients, doses, etc.) and alternative medicine
- Addictions (smoking, alcohol...)
- Drug adherence
List and grade (NCI version 4) of clinical signs and laboratory abnormalities:
- The biological data will be obtained on the basis of biological test results addressed to the oncologist and all other test results provided by the patient
- Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment (level 3 pharmaceutical analysis according to the criteria of the French Society of Clinical Pharmacy) in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy (18).
The third step of the consultation consists on providing "pharmaceutical interventions" following the pharmaco-therapeutic analysis (18).
These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. These interventions will be done in the absolute respect for the French Code of Public Health. All these interventions will be documented, tracked, and evaluated, particularly in terms of acceptance by prescribers.
Sample size Both centers have the necessary number of patients needed to ensure the proper recruitment required for the study.
The annual throughput of the AP-HM is about 300 patients. Targeted diseases as part of this research project are gastrointestinal tumors (GIST, colorectal), neuroendocrine, renal, gynecological, urological (prostate) and skin (melanoma) cancers. The annual throughput of Grenoble University Hospital is more than 70 patients. Targeted diseases are renal tumors, breast and colorectal cancers.
The number of subjects to be included required is determined from the primary endpoint, namely the rate of adverse events of grade III-IV. Data from the current practice in the main center (AP- HM) and from the literature estimate this rate at 35%.
The majority of adverse events related to drugs being preventable, the investigators estimate a decrease of 20 points in this rate in the experimental arm, that is to say a rate of 15%. 166 subjects (83 per group) are needed for a power of 90% and an alpha risk of 5%. To compensate the potential lost of the out of sights (estimated around 15%), the investigators will include 190 subjects in total.
The sample size was determined to obtain 90% power to detect a 20 percent difference in between the 2 groups, as this difference is considered to be clinically significant. In accordance with previous studies (26-31), the investigators hypothesized that the occurrence of the primary endpoint will be at 35% in the control group. With the threshold for statistical significance set at a p-value of 0.05 (two-sided alpha), these calculations showed that 166 patients are needed (83 per group). Assuming that potentially 15% of patients will be lost to follow-up, a total of 190 individuals need to be included.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Marseille, France
- Hôpital de la Timone Assistance Publique Hôpitaux de Marseille
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adult patients over 18 years of both sexes
- Patients with cancer pathology whatever stage/grade and associated comorbidities he has
- Patients treated with oral cancer therapy for less than a month regardless of the therapy line
- Have accepted to participate and signed the non-opposition form
Exclusion Criteria:
- Patients less than 18 years of age and all vulnerable people, in accordance with French laws (pregnant women, adults under guardianship or trusteeship; persons deprived of liberty)
- Patients under treatment for more than one month
- Patients refusing to participate in the research project
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Autre: standard course
The patients in the control group will have a "classic" course of treatment. They will receive -An educational assessment consisting on evaluating the patient's educational needs.
Moreover, in the control arm, a systematic "short pharmaceutical interview" with an average duration of 15 minutes will be proposed to patients at the initiation of treatment, at D15 after the prescription (considered as the date of inclusion) at M1 and then every 3 months (M3, M6, M9 and M12): |
|
Autre: Long Pharmaceutical Consultations
The patients will receive the same course of treatment as in the control group, including the D0 short pharmaceutical interview, with the same prerogatives of acceptance or rejection of participation in the TPE program.
Short pharmaceutical interviews from D15 to M12 will be replaced by long pharmaceutical consultations of 30 to 60 minutes.
The latter consisting in a full clinical medication review and incorporating the pedagogic aspects addressed in the short pharmaceutical interviews but for all therapeutic drugs taken by the patient.
Additional consultations are possible on the request of the oncologist and/or patient.
The consultations carried out at the request of the oncologist and/or the patient will be counted The first part of the pharmaceutical consultation focuses on a complete clinical medication review including Establishment of the patient profile: medical history, drug allergies and intolerance, comorbidities, age, understanding capacities, organizational capacity
|
The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient. Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing "pharmaceutical interventions" following the pharmaco-therapeutic analysis (18). These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Rate of grade III-IV adverse events defined by the NCI criteria
Délai: 6 months
|
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Adverse events by the NCI criteria
Délai: 1st, 3rd, 6th, 9th, 12th months of the study
|
1st, 3rd, 6th, 9th, 12th months of the study
|
Satisfaction toward the treatment: satisfaction with medicines questionnaire ((SatMed-Q®)
Délai: 1st, 3rd, 6th, 9th, 12th months of the study
|
1st, 3rd, 6th, 9th, 12th months of the study
|
The number of visit to the emergency services
Délai: 1st, 3rd, 6th, 9th, 12th months of the study
|
1st, 3rd, 6th, 9th, 12th months of the study
|
The number of hospitalizations
Délai: 1st, 3rd, 6th, 9th, 12th months of the study
|
1st, 3rd, 6th, 9th, 12th months of the study
|
The number of additional medical consultations
Délai: 1st, 3rd, 6th, 9th, 12th months of the study
|
1st, 3rd, 6th, 9th, 12th months of the study
|
Drug adherence: Morisky scale 8-item;
Délai: 1st, 3rd, 6th, 9th, 12th months of the study
|
1st, 3rd, 6th, 9th, 12th months of the study
|
Quality of life: Short Form 36 (SF-36) questionnaire
Délai: 1st, 3rd, 6th, 9th, 12th months of the study
|
1st, 3rd, 6th, 9th, 12th months of the study
|
Survival: RECIST criteria
Délai: 1st, 3rd, 6th, 9th, 12th months of the study
|
1st, 3rd, 6th, 9th, 12th months of the study
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 2015-03
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Oral Anticancer Therapy.
-
University of California, DavisRenew Life Formulas IncComplétéMicrobiote oralÉtats-Unis
-
Wyeth is now a wholly owned subsidiary of PfizerComplété
-
University of Southern CaliforniaUnited States Department of DefenseComplété
-
Regenex Pharmaceutical, ChinaInconnueContraceptif oralChine
-
Samara State Medical UniversityRecrutementMicrobiote oralFédération Russe
-
BayerComplétéContraceptif oralSuisse, Le Portugal, Chili, Italie, Corée, République de, Venezuela, Philippines, Colombie, Thaïlande, Argentine, Allemagne, Fédération Russe, Royaume-Uni, République tchèque
-
BayerComplétéContraceptif oralAllemagne
-
Teva Branded Pharmaceutical Products R&D, Inc.ComplétéContraceptif oral | HémostaseAllemagne, Israël, Italie, Espagne
-
Teva Women's HealthComplétéContraceptif oral | HémostaseÉtats-Unis, Italie
Essais cliniques sur No Pharmaceutical Consultations
-
University of Massachusetts, WorcesterNational Institute on Minority Health and Health Disparities (NIMHD)Actif, ne recrute pasHypertensionÉtats-Unis
-
Institute of Medical Biology, Chinese Academy of...Hebei Provincial Center for Diseases Control and PreventionComplété
-
Otsuka Pharmaceutical Factory, Inc.CelerionComplété
-
University of MinnesotaComplété
-
Assistance Publique - Hôpitaux de ParisComplété
-
Milton S. Hershey Medical CenterPas encore de recrutementMaladies du foie | NASH - Stéatohépatite non alcoolique | NASH
-
University of CologneComplétéAccident vasculaire cérébral | ApraxieAllemagne
-
Northwestern UniversityComplétéLa dépression | AnxiétéÉtats-Unis
-
Eunah Cho, MDComplétéRécupération postopératoireCorée, République de
-
H2O Health and Agriculture LLCInconnuePneumonie | DiarrhéeGuatemala